ABSTRACT
The infiltration by numerous osteoclastic giant cells is a frequent finding in bone tumors and pseudo-tumors. Pathologists must integrate clinical and radiological data to achieve a correct diagnosis in bone pathology. Benign giant-cell rich lesions of bone encompass giant cell tumor of bone, aneurysmal bone cyst, chondroblastoma, brown tumor and fibrous cortical defect/non-ossifying fibroma. Amongst malignant neoplasms, variants of conventional osteosarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma and bone metastasis must be discussed. Recently, new diagnostic markers, antibodies for immuno-histochemistry and genetic markers, have been developed and are helpful to diagnose such lesions.
Subject(s)
Bone Diseases/pathology , Bone Neoplasms/pathology , Giant Cells/pathology , Biomarkers, Tumor/analysis , Bone Cysts, Aneurysmal/chemistry , Bone Cysts, Aneurysmal/diagnosis , Bone Cysts, Aneurysmal/pathology , Bone Diseases/diagnosis , Bone Diseases/metabolism , Bone Neoplasms/chemistry , Bone Neoplasms/diagnosis , Bone Neoplasms/secondary , Chondroblastoma/chemistry , Chondroblastoma/diagnosis , Chondroblastoma/pathology , Diagnosis, Differential , Fibroma, Ossifying/chemistry , Fibroma, Ossifying/diagnosis , Fibroma, Ossifying/pathology , Genetic Markers , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/diagnosis , Giant Cell Tumor of Bone/pathology , Humans , Immunohistochemistry/methods , Molecular Diagnostic Techniques , Sarcoma/chemistry , Sarcoma/diagnosis , Sarcoma/pathologyABSTRACT
Specific H3F3A driver mutations and IDH2 mutations were recently described in giant cell tumor of bone (GCTB) and H3F3B driver mutations in chondroblastoma; these may be helpful as a diagnostic tool for giant cell-containing tumors of the bone. Using Sanger sequencing, we determined the frequency of H3F3A, H3F3B, IDH1, and IDH2 mutations in GCTBs (n=60), chondroblastomas (n=12), and other giant cell-containing tumors (n=24), including aneurysmal bone cyst, chondromyxoid fibroma, and telangiectatic osteosarcoma. To find an easy applicable marker for H3F3A mutation status, H3K36 trimethylation and ATRX expression were correlated with H3F3A mutations. In total, 69% of all GCTBs harbored an H3F3A (G34W/V) mutation compared with 0% of all other giant cell-containing tumors (P<0.001), whereas 70% of chondroblastomas showed an H3F3B (K36M) mutation compared with 0% of other giant cell-containing tumors (P<0.001). Diffuse H3K36 trimethylation positivity was more often seen in mutated H3F3A GCTBs compared with other giant cell-containing tumors (P=0.005). ATRX protein expression was not correlated with H3F3A mutation status. Hotspot mutations in IDH1 or IDH2 were absent. Our results show that H3F3A and H3F3B mutation analysis appears to be a highly specific, although less sensitive, diagnostic tool for the distinction of GCTB and chondroblastoma from other giant cell-containing tumors. Although H3K36 trimethylation and ATRX immunohistochemistry cannot be used as surrogate markers for H3F3A mutation status, mutations in H3F3A are associated with increased H3K36 trimethylation, suggesting that methylation at this residue may play a role in the etiology of the disease.
Subject(s)
Biomarkers, Tumor/genetics , Bone Neoplasms/genetics , Chondroblastoma/genetics , DNA Mutational Analysis , Giant Cell Tumor of Bone/genetics , Histones/genetics , Mutation , Adolescent , Adult , Aged , Biomarkers, Tumor/analysis , Biopsy , Bone Neoplasms/chemistry , Bone Neoplasms/pathology , Chondroblastoma/chemistry , Chondroblastoma/pathology , DNA Helicases/analysis , Diagnosis, Differential , Female , Genetic Predisposition to Disease , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/pathology , Histones/analysis , Humans , Immunohistochemistry , Isocitrate Dehydrogenase/genetics , Male , Methylation , Middle Aged , Nuclear Proteins/analysis , Phenotype , Predictive Value of Tests , Tissue Array Analysis , X-linked Nuclear Protein , Young AdultABSTRACT
BACKGROUND: Giant cell tumor of bone (GCT) is a potentially malignant tumor. CD147 is a multifunctional protein, which expresses itself in many tumors. In this study, we have investigated the correlation between CD147 and PCNA, VEGF, MMPs expression in giant cell tumor of bones. We have also explored the relationship between its clinical pathology and prognosis. RESULTS: A significant difference of the expression level of CD147, MMPs was found in cases of GCT with Jaffe grading and prognosis (P<0.05). But, it was not in accordance with the patient's age and sex. An expression of CD147 was positively correlated with MMP-9, VEGF, MVD, PCNA (r=0.271, P=0.025; r=0.411, P=0.000; r=0.872, P=0.000; r=0.394, P=0.001). CONCLUSION: The expression level of CD147 in giant cell tumors of bones is correlated with the development of cancers and relapse. There was a positive correlation between expressions of CD147 and MMP-9, VEGF, MVD, PCNA, and CD147. This is an important indicator in evaluating the malignant degree and prognosis of giant cell tumors of bone. It may be the new target for ensuring chemopreventive strategies.
Subject(s)
Basigin/analysis , Bone Neoplasms/chemistry , Giant Cell Tumor of Bone/chemistry , Matrix Metalloproteinase 9/analysis , Proliferating Cell Nuclear Antigen/analysis , Vascular Endothelial Growth Factor A/analysis , Adolescent , Adult , Bone Neoplasms/pathology , Child , Female , Giant Cell Tumor of Bone/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Grading , Predictive Value of Tests , Young AdultABSTRACT
INTRODUCTION: Giant cell lesions are characterised histologically by multinucleated giant cells in a background of ovoid to spindle-shaped mesenchymal cells. There is a major debate whether these lesions are separate entities or variants of the same disease. Our aim was to study the nature of multinucleated and mononuclear cells from peripheral giant cell granuloma (PGCG), and central giant cell granuloma (CGCG) and giant cell tumor (GCT) of long bones using immunohistochemistry evaluation and to determine whether there is a correlation between recurrence and the markers used. MATERIALS AND METHODS: Ki-67, p53, Vimentin, smooth muscle specific actin, CD68 and alpha-1-antichymotrypsin were used to study 60 giant cell lesions. These included 26 CGCG, 28 PGCG, and 6 GCT cases using an avidin-biotin-complex immunohistochemistry standard method. RESULTS: All studied cases showed the same results except the percentage of Ki-67 positive mononuclear cells in PGCG was significantly higher than that of both CGCG and GCT (p<0.05). Interestingly, no statistical correlation between recurrence and the markers used was found. CONCLUSION: Our results may suggest that these lesions have the same histogenesis. The mononuclear stromal cells, both histiocytic and myofibroblastic, are thought to be responsible for the behavior of these lesions whereas the multinucleated cells are considered as reactive. This might support the argument that PGCG, CGCG and GCT are different variants for the same disease. Further studies using molecular techniques are required to elucidate why some of these lesions behave aggressively than others.
Subject(s)
Actins/analysis , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Granuloma, Giant Cell/metabolism , Jaw Diseases/metabolism , Ki-67 Antigen/analysis , Serine Proteinase Inhibitors/analysis , Tumor Suppressor Protein p53/analysis , Vimentin/analysis , alpha 1-Antichymotrypsin/analysis , Adolescent , Adult , Aged , Bone Neoplasms/chemistry , Child , Female , Femur/chemistry , Giant Cell Tumor of Bone/chemistry , Humans , Immunohistochemistry , Male , Middle Aged , Recurrence , Young AdultABSTRACT
Giant cell tumor of bone (GCTb) represents 5% of bone tumors, and although considered benign, 5% metastasize to the lung. The expression of proteins directly or indirectly associated with osteolysis and tumor growth was studied on 163 samples of GCTb. Of these, 33 patients developed lung metastasis during follow-up. The impact of tumor-host interaction on clinical aspects was evaluated with the aim of finding specific markers for new biological therapies, thus improving clinical management of GCTb. Protein expression was evaluated by immunohistochemical analysis on Tissue Microarray. The majority of GCTb samples from patients with metastatic disease were strongly positive to RANKL and its receptor RANK as well as to CAII and MMP-2 and to pro-survival proteins NFIB and c-Fos. Kaplan-Meier analysis indicated a significant difference in metastasis free survival curves based on protein staining. Interestingly, the statistical correlation established a strong association between all variables studied with a higher τ coefficient for RANK/RANKL, RANK/NFIB, and RANKL/NFIB pairs. At multivariate analysis co-overexpression of NFIB, RANK and RANKL significantly increased the risk of metastasis with an odds ratio of 13.59 (95%CI 4.12-44.82; p < 0.0005). In conclusion, the interconnection between matrix remodeling and tumor cell activity may identify tumor-host endpoints for new biological treatments.
Subject(s)
Bone Neoplasms/mortality , Giant Cell Tumor of Bone/mortality , NFI Transcription Factors/physiology , Adult , Aged , Bone Neoplasms/chemistry , Bone Neoplasms/pathology , Bone Remodeling , Female , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/pathology , Humans , Male , Middle Aged , Prognosis , RANK Ligand/analysis , Receptor Activator of Nuclear Factor-kappa B/analysis , Retrospective StudiesABSTRACT
The nature of the mononuclear stromal cells (MSCs) in giant cell tumor of bone (GCTB) has not been thoroughly investigated. The purpose of this study was to evaluate the degree and significance of myofibroblastic differentiation in 18 cases of GCTB by immunohistochemistry (IH) and/or electron microscopy (EM). All immunostained cases were found positive for smooth muscle actin (SMA) and/or muscle specific actin (MSA), most in 1-33% of the MSCs. Ultrastructurally, most MSCs were fibroblasts, and a significant number of cells displayed myofibroblastic differentiation. Myofibroblasts are an important component of MSCs in GCTB. The myofibroblastic population may be responsible in part for the production of matrix metalloproteinases (MMPs), which probably play a role in bone destruction, tumor aggression, and recurrence.
Subject(s)
Biomarkers, Tumor/analysis , Bone Neoplasms , Cell Differentiation , Giant Cell Tumor of Bone , Immunohistochemistry , Microscopy, Electron , Myofibroblasts , Stromal Cells , Actins/analysis , Adolescent , Adult , Biopsy , Bone Neoplasms/chemistry , Bone Neoplasms/ultrastructure , Female , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/ultrastructure , Humans , Male , Middle Aged , Myofibroblasts/chemistry , Myofibroblasts/ultrastructure , Predictive Value of Tests , Prognosis , Stromal Cells/chemistry , Stromal Cells/ultrastructure , Young AdultABSTRACT
BACKGROUND AND PURPOSE: Giant cell tumor of bone (GCT) is sometimes difficult to distinguish from other giant-cell-rich tumors such as chondroblastoma (CHB) and aneurysmal bone cyst (ABC). The usefulness of p63 as a diagnostic marker for GCT is controversial. While there have been no reports about p63 as a prognostic marker for local recurrence, various p63-positive rates in GCT have been reported. The purpose of this study was to investigate retrospectively whether p63 is useful as a diagnostic marker and/or a prognostic marker for local recurrence of GCT. METHODS: This study included 36 patients diagnosed with either GCT (n = 16), CHB (n = 9), ABC (n = 7), or non-ossifying fibroma (NOF) (n = 4). p63 immunostaining was performed for all specimens. The mean p63-positive rate was compared with the four diseases and between the recurrent and non-recurrent cases of GCT. RESULTS: Although the mean p63-positive rate for GCT (36.3%) was statistically higher than that of all other diseases examined (CHB: 15.2%; ABC: 5.8%; NOF: 3.4%), p63 was not specific for GCT. The mean p63-positive rate for recurrent GCT cases (73.6%) was statistically higher than that for non-recurrent cases (29.1%). CONCLUSION: In the diagnosis of GCT, p63 is a useful but not a conclusive marker. However, p63 did appear to indicate the biological aggressiveness of GCT. Therefore, p63 may help surgeons to estimate the risk of recurrence after surgery and help them to choose the best treatment for each GCT case.
Subject(s)
Bone Neoplasms/chemistry , Giant Cell Tumor of Bone/chemistry , Membrane Proteins/analysis , Neoplasm Recurrence, Local/etiology , Adolescent , Adult , Bone Neoplasms/diagnosis , Female , Giant Cell Tumor of Bone/diagnosis , Humans , Male , Membrane Proteins/physiology , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND: Multinucleated giant cell-containing tumors and pseudotumors of bone represent a heterogeneous group of benign and malignant lesions. Differential diagnosis can be challenging, particularly in instances of limited sampling. The purpose of this study was to evaluate the contribution of the P63 in the positive and differential diagnosis of giant cell tumor of bone. METHODS: This study includes 48 giant cell-containing tumors and pseudotumors of bone. P63 expression was evaluated by immunohistochemistry. Data analysis was performed using Epi-info software and SPSS software package (version 17). RESULTS: Immunohistochemical analysis showed a P63 nuclear expression in all giant cell tumors of bone, in 50% of osteoid osteomas, 40% of aneurysmal bone cysts, 37.5% of osteoblastomas, 33.3% of chondromyxoide fibromas, 25% of non ossifiant fibromas and 8.3% of osteosarcomas. Only one case of chondroblastoma was included in this series and expressed p63. No P63 immunoreactivity was detected in any of the cases of central giant cell granulomas or langerhans cells histiocytosis. The sensitivity and negative predictive value (NPV) of P63 immunohistochemistry for the diagnosis of giant cell tumor of bone were 100%. The specificity and positive predictive value (PPV) were 74.42% and 59.26% respectively. CONCLUSIONS: This study found not only that GCTOB expresses the P63 but it also shows that this protein may serve as a biomarker for the differential diagnosis between two morphologically similar lesions particularly in instances of limited sampling. Indeed, P63 expression seems to differentiate between giant cell tumor of bone and central giant cell granuloma since the latter does not express P63. Other benign and malignant giant cell-containing lesions express P63, decreasing its specificity as a diagnostic marker, but a strong staining was seen, except a case of chondroblastoma, only in giant cell tumor of bone. Clinical and radiological confrontation remains essential for an accurate diagnosis. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1838562590777252.
Subject(s)
Biomarkers, Tumor/analysis , Bone Neoplasms/chemistry , Giant Cell Tumor of Bone/chemistry , Transcription Factors/analysis , Tumor Suppressor Proteins/analysis , Adolescent , Adult , Bone Neoplasms/pathology , Cell Nucleus/chemistry , Child , Diagnosis, Differential , Female , Giant Cell Tumor of Bone/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Morocco , Predictive Value of Tests , Sensitivity and Specificity , Young AdultABSTRACT
Giant cell angioblastoma (GCAB) is an extremely rare soft tissue tumor of early childhood and only five cases have been described to date. As such the clinical, pathological, and prognostic features are poorly defined. We prensent here a new case of GCAB in bone of a child aged 4-years old. The lesion was composed of dense and loose cell regions. The dense regions were characterized by nodular, linear, and plexiform aggregates of oval- to spindle-shaped tumor cells around small vascular channels and interspersed with large mononuclear cells and multinucleate giant cells. The loose cell areas were characterized by distributed fibroblasts and abundant myxoid matrix, which diminished with patient age. Infiltrative growth was observed in some areas. Oval-to-spindle cells showed positivity for Vimentin, CD31 and CD34 staining, and partial positivity for smooth muscle actin. Mononuclear cells and multinucleate giant cells showed Vimentin and CD68 positivity. Seventeen months after thorough curettage of the lesion, a local recurrence was found. Based upon the clinical, histological and immunohistochemical findings, infiltrate condition, and prognosis, we classified GCAB into two subtypes. Type I does not infiltrate surrounding tissues and has good prognosis. Type II infiltrates the surrounding tissues, relapses earlier, and has worse prognosis. This report augments the limited GCAB literature to promote our understanding and guide therapy of this rare disease. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6699811297488137.
Subject(s)
Femoral Neoplasms/pathology , Giant Cell Tumor of Bone/pathology , Biomarkers, Tumor/analysis , Child, Preschool , Curettage , Diagnosis, Differential , Femoral Neoplasms/chemistry , Femoral Neoplasms/surgery , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/surgery , Humans , Immunohistochemistry , Male , Neoplasm Invasiveness , Neoplasm Recurrence, Local , Predictive Value of Tests , Time Factors , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
BACKGROUND AND PURPOSE: Giant cell tumor (GCT) of the small bones (small-bone GCT) is usually rare and considered somewhat different from conventional GCT. The purpose of this study was to investigate and report the clinicopathological features of 11 cases with small-bone GCT. MATERIALS AND METHODS: Patient information was obtained with the help of questionnaires. X-rays and paraffin blocks obtained from several institutions were clinically, radiographically, and histologically evaluated. RESULTS: Small-bone GCT was observed in younger patients compared to conventional GCT; 5 of the 11 (45%) patients were below 20 years of age, whereas the corresponding figure for all GCT patients is 16% in Japan. Excessive cortical bone expansion is a special feature. There were two cases of recurrence and one case of lung metastasis; the primary lesion was in the hand for all three cases. In contrast, no primary lesion of the foot recurred or metastasized. Varying degrees of positive p63 immunostaining were observed in all examined cases (n = 9) of small-bone GCT but were negative in case of giant cell reparative granuloma (GCRG) and solid variant of aneurysmal bone cyst (ABC). One case that demonstrated high-intensity positive staining had two episodes of recurrence. CONCLUSION: Small-bone GCT tends to develop in younger patients than does conventional GCT. Primary GCTs of the hand may be biologically more aggressive than those of the feet. The p63 immunostaining may be useful not only for differential diagnosis but also for prognostication of small-bone GCT.
Subject(s)
Bone Neoplasms/pathology , Giant Cell Tumor of Bone/pathology , Adolescent , Adult , Bone Neoplasms/chemistry , Bone Neoplasms/diagnostic imaging , Child , Female , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/diagnostic imaging , Humans , Immunohistochemistry , Male , Membrane Proteins/analysis , Middle Aged , RadiographyABSTRACT
Multicentric giant-cell tumors of the bone (GCTs) are rare. Little is known about the mechanisms by which these tumors spread and how 1% of GCT turn out to be multicentric. We report the case of a 19-year-old woman with metachronous multiple and recurrent GCTs that were unusual in their pattern of progression along the right lower limb over a 23-year period. Histology showed no evidence of malignant transformation. The treatment was repeated curettage and packing with cement. This did not permit a wide surgical margin, but avoided amputation and preserved full limb function. We tested the proliferation index marker Ki-67 in the tumor specimens. Ki-67 expression was limited to the mononuclear cell component of the tumors. The proliferation index was similar in each new tumor and higher in recurrences for each location. In this case, proliferation was initially low in the new tumor location, despite the time difference and independent from the initial clone evolution. Proliferation index increased in recurrent GCTs after marginal margin resection.
Subject(s)
Bone Neoplasms/pathology , Giant Cell Tumor of Bone/pathology , Ki-67 Antigen/analysis , Neoplasms, Second Primary/pathology , Adult , Biomarkers, Tumor/analysis , Bone Neoplasms/chemistry , Bone Neoplasms/surgery , Cell Division , Disease-Free Survival , Female , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/surgery , Humans , Lower Extremity , Neoplasm Recurrence, Local , Neoplasms, Second Primary/chemistry , Neoplasms, Second Primary/surgery , RadiographyABSTRACT
Fibroblastlike stromal cells, which are always present as a component of giant cell tumor of bone (GCT), can be observed in both in vivo and cultured cell samples. Although they are assumed to trigger the cancer process in GCT, the histogenesis of GCT stromal cells is poorly understood. It is known that mesenchymal stem cells (MSCs) can develop to osteoblasts. Evidence has been presented that GCT stromal cells can also develop to osteoblasts. A connection between MSCs and GCT stromal cells was sought by using 2 different laboratory approaches. First, immunohistological analyses revealed that some of the same markers, detected by the SH2, SH3, and SH4 antibodies and the CD166 antigen, were found in GCT stromal cells as in the first developmental stages of osteoblast differentiation from the initial MSCs. These immunohistological findings could be confirmed by reverse transcriptase polymerase chain reaction. Second, cellular differentiation by morphology and lineage-specific staining offered evidence that not only osteoblasts, but also chondroblasts and adipocytes, could be cultured from stromal cells. The presented double approach indicates that GCT stromal cells can originate from MSCs.
Subject(s)
Bone Neoplasms/pathology , Fibroblasts/pathology , Giant Cell Tumor of Bone/pathology , Adipocytes/cytology , Adolescent , Adult , Biomarkers, Tumor/analysis , Bone Neoplasms/chemistry , Chondrocytes/cytology , DNA Primers/chemistry , Fibroblasts/chemistry , Fluorescent Antibody Technique, Indirect , Giant Cell Tumor of Bone/chemistry , Humans , Middle Aged , Osteoclasts/chemistry , Osteoclasts/pathology , RNA, Neoplasm/analysis , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/chemistry , Stromal Cells/pathology , Tumor Cells, CulturedABSTRACT
This study aims to investigate the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in giant cell tumor of bone (GCT) and other osteolytic lesions in bone. By using semi-quantitative RT-PCR, we showed that three major isoforms of VEGF (121, 165 and 189) were expressed in GCTs, with isoform 121 being the most abundant. The expression levels of VEGF and MMP-9 mRNA were significantly higher in advanced GCTs (stage II/III) than in stage I GCTs. We further elucidated the cellular localization of VEGF and MMP-9 gene transcripts in GCT and other osteolytic lesions using an in situ hybridization assay. The results showed that stromal tumor cells and osteoclast-like giant cells of GCT, fibrous stromal cells in anuerysmal bone cysts and fibrous dysplasia, and Langerhans-type giant cells as well as histocytes in eosinophillic granuloma, were all strongly positive for VEGF and MMP-9 mRNA expression. In a prospective study, we performed VEGF and MMP-9 immuno-staining on paraffin sections of pathological tissues harvested from 48 patients (14 GCT, 10 anuerysmal bone cysts, 10 eosinophillic granuloma, 4 fibrous dysplasia, 2 simple bone cyst, 2 osteomyelitis and 6 patients with fractured femoral head as control). The results showed that the differences in VEGF and MMP-9 expression between Stage I and other advanced Stages (II, III and recurrent) were highly significant (p<0.001), with advanced stages showing a higher mean expression. The difference between recurrent and Stage II and III lesions, was also statistically significant (p=0.03 for VEGF, and p=0.01 for MMP-9 expression), with recurrent lesions showing a higher mean expression of both VEGF and MMP-9. In conclusion, VEGF and MMP-9 expression in osteolytic lesions of bone co-relates well with the extent of bone destruction and local recurrence. Their expression may therefore provide some prognostic indication of the possible aggressive behavior of the underlying pathology.
Subject(s)
Bone Neoplasms/chemistry , Endothelial Growth Factors/genetics , Giant Cell Tumor of Bone/chemistry , Intercellular Signaling Peptides and Proteins/genetics , Lymphokines/genetics , Matrix Metalloproteinase 9/genetics , Osteolysis/metabolism , Bone Cysts/metabolism , Bone Cysts, Aneurysmal/metabolism , Bone Neoplasms/pathology , Endothelial Growth Factors/analysis , Fibrous Dysplasia of Bone/metabolism , Gene Expression , Giant Cell Tumor of Bone/pathology , Granuloma/metabolism , Histiocytes/chemistry , Humans , Immunohistochemistry , In Situ Hybridization , Intercellular Signaling Peptides and Proteins/analysis , Lymphokines/analysis , Matrix Metalloproteinase 9/analysis , Neoplasm Recurrence, Local , Neoplasm Staging , Osteoclasts/chemistry , Osteomyelitis/metabolism , Prospective Studies , Protein Isoforms/genetics , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/chemistry , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
Giant cell tumors (GCTs) of the bone are primary skeletal neoplasms that behave intermediately between a true benign and an overtly malignant neoplasm. For two decades, controversial reports have found estrogen receptor (ER) expression in isolated cells or small numbers of samples from these tumors. In this report, we studied by immunohistochemistry 88 cases of GCTs and found that 51% of the samples expressed ER. Furthermore, we found that a subset of seven samples analyzed for ER expression by western blot was positive. To address whether the ER expressed in these samples could be functional, isolated cells were exposed to beta-estradiol and growth curves were generated. Exposure of cells to beta-estradiol induced a small but significant growth in the cells. These results strongly support that GCTs of the bone express functional ERs.
Subject(s)
Bone Neoplasms/chemistry , Giant Cell Tumor of Bone/chemistry , Receptors, Estrogen/analysis , Blotting, Western , Bone Neoplasms/pathology , Cell Division/drug effects , Estradiol/pharmacology , Female , Giant Cell Tumor of Bone/pathology , Humans , Immunohistochemistry , Male , Receptors, Estrogen/physiologyABSTRACT
BACKGROUND: The purpose of this study is the evaluation of certain markers determining the prognosis of giant cell tumor of bone. METHODS: A clinicopathological analysis of 15 cases of giant cell tumor is presented. RESULTS: Giant cell tumor of bone mainly affects women with an average age of 34 years and is located in the upper and distal ends of the long tubular bones (93.3%). 60% of the tumor biopsies was Grade I, 33.3 % Grade II and 6.7% Grade III. The recurrence rate was 33.3% and the malignant transformation was 13.3%. CONCLUSIONS: Prognosis of giant cell tumor of bone is likely to be mistaken if it is based only on the histological picture. On the contrary, considering important parameters, such as tumor location, size and tumor aggressiveness, frequency of recurrences and type of surgical management, one may predict in most cases the clinical outcome of the neoplastic process.
Subject(s)
Bone Neoplasms/pathology , Giant Cell Tumor of Bone/pathology , Adolescent , Adult , Age Distribution , Aged , Biomarkers, Tumor/analysis , Bone Neoplasms/chemistry , Bone Neoplasms/therapy , Female , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/therapy , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Prognosis , Sex Distribution , Treatment OutcomeABSTRACT
The authors examined the distribution of tumor growth factor-beta (TGF-beta) isoforms and receptors in 35 giant cell tumor (GCT) of bone in comparison with a group of benign giant cell-containing lesions of bone, including 5 aneurysmal bone cysts, 2 cases of brown tumor of hyperparathyroidism, 3 nonossifying fibromas, and 7 cases of giant cell reparative granuloma. The results of immunohistochemical analysis of GCT showed a complete absence of TGF-beta1 expression in both mononuclear tumor cells and giant cells. Only reactive bone present within the tumor showed an intense immunoreactivity. Transforming growth factor-beta2 and TGF-beta3 were detected in the majority of cases (97.1% and 82.8%, respectively), whereas TGF-beta receptor type I (TGF-beta RI) and type II (TGF-beta RII) were diffusely expressed in all cases. Reverse transcription-polymerase chain reaction (RT-PCR) analysis performed on 10 GCTs with specific oligonucleotide primers demonstrated the presence of mRNA transcripts for TGF-beta1, 2, 3, and for TGF-beta RI and RII. Quantitative measurements of TGF-beta1 in conditioned media from primary cultures of GCT showed undetectable or very low amounts of the cytokine (0-23 pg/mL). The results of immunohistochemical analysis showed that all giant cell-containing lesions of bone were at least focally positive for the 3 isoform of TGF-beta, with positivity present both in osteoclast-like giant cells and mononuclear cells, and diffusely positive for TGF-beta RI and RII. Reverse transcription-polymerase chain reaction analysis conducted on samples from 3 nonossifying fibromas and 1 giant cell reparative granuloma confirmed the expression of the corresponding mRNA. In conclusion, according to the current data, GCT of bone can be distinguished from other giant cell-containing lesions of bone on the basis of the absence of TGF-beta1 expression at the protein level, which appears to be the result of posttranslational regulation processes.
Subject(s)
Bone Neoplasms/chemistry , Bone and Bones/chemistry , Giant Cell Tumor of Bone/chemistry , Receptors, Transforming Growth Factor beta/analysis , Transforming Growth Factor beta/analysis , Adult , Bone Neoplasms/pathology , Bone and Bones/pathology , Cells, Cultured , Female , Giant Cell Tumor of Bone/pathology , Humans , Immunohistochemistry , Male , Protein Isoforms/analysis , Receptors, Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/geneticsABSTRACT
OBJECTIVE: Osteoclast differentiation factor (ODF; also known as osteoprotegerin ligand, receptor activator of nuclear factor kappaB ligand, and tumor necrosis factor-related activation-induced cytokine) is a recently described cytokine known to be critical in inducing the differentiation of cells of the monocyte/macrophage lineage into osteoclasts. The role of osteoclasts in bone erosion in rheumatoid arthritis (RA) has been demonstrated, but the exact mechanisms involved in the formation and activation of osteoclasts in RA are not known. These studies address the potential role of ODF and the bone and marrow microenvironment in the pathogenesis of osteoclast-mediated bone erosion in RA. METHODS: Tissue sections from the bone-pannus interface at sites of bone erosion were examined for the presence of osteoclast precursors by the colocalization of messenger RNA (mRNA) for tartrate-resistant acid phosphatase (TRAP) and cathepsin K in mononuclear cells. Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to identify mRNA for ODF in synovial tissues, adherent synovial fibroblasts, and activated T lymphocytes derived from patients with RA. RESULTS: Multinucleated cells expressing both TRAP and cathepsin K mRNA were identified in bone resorption lacunae in areas of pannus invasion into bone in RA patients. In addition, mononuclear cells expressing both TRAP and cathepsin K mRNA (preosteoclasts) were identified in bone marrow in and adjacent to areas of pannus invasion in RA erosions. ODF mRNA was detected by RT-PCR in whole synovial tissues from patients with RA but not in normal synovial tissues. In addition, ODF mRNA was detected in cultured adherent synovial fibroblasts and in activated T lymphocytes derived from RA synovial tissue, which were expanded by exposure to anti-CD3. CONCLUSION: TRAP-positive, cathepsin K-positive osteoclast precursor cells are identified in areas of pannus invasion into bone in RA. ODF is expressed by both synovial fibroblasts and by activated T lymphocytes derived from synovial tissues from patients with RA. These synovial cells may contribute directly to the expansion of osteoclast precursors and to the formation and activation of osteoclasts at sites of bone erosion in RA.
Subject(s)
Arthritis, Rheumatoid/metabolism , Carrier Proteins/biosynthesis , Membrane Glycoproteins/biosynthesis , Synovial Membrane/chemistry , Bone Marrow Cells/metabolism , Bone Neoplasms/chemistry , Bone Neoplasms/metabolism , Bone Resorption/metabolism , Cathepsin K , Cathepsins/genetics , Gene Expression , Giant Cell Tumor of Bone/chemistry , Giant Cell Tumor of Bone/metabolism , Humans , Osteoclasts/physiology , RANK Ligand , Receptor Activator of Nuclear Factor-kappa B , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
A human in vitro resorption assay has been developed using osteoclastoma-derived osteoclasts and used to evaluate novel antiresorptive agents including antagonists of the alphavbeta3 integrin, and inhibitors of cathepsin K and the osteoclast ATPase. The potency of novel compounds in the in vitro resorption assay correlates with functional assays for each class of inhibitor: the human alphavbeta3-mediated cell adhesion assay for the vitronectin receptor antagonists (r2 = 0.82), the chick osteoclast vacuolar ATPase enzyme assay for the H+-ATPase inhibitors (r2 = 0.77) and the recombinant human cathepsin K enzyme assay for the cathepsin K inhibitors (r2 = 0.80). Cell suspensions, rich in osteoclasts, are prepared by collagenase digestion of the tumor tissue. These cells can be stored long-term in liquid nitrogen and upon thawing maintain their bone-resorbing phenotype. The cryopreserved cells can be cultured on bovine cortical bone for 24-48 h and resorption can be measured by either confocal microscopy or biochemical assays. The resorptive activity of osteoclasts derived from a number of tumors can be inhibited reproducibly using a number of mechanistically unique antiresorptive compounds. In addition, the measurement of resorption pits by laser confocal microscopy correlates with the release of type I collagen C-telopeptides or N-telopeptides, as measured by enzyme-linked immunosorbent assay. Resorption can be measured reproducibly using a 48-h incubation of osteoclasts on bone slices, or a 24-h incubation with bone particles. This in vitro human osteoclast resorption assay provides a robust system for the evaluation of inhibitors of osteoclastic function that may be developed for the treatment of metabolic bone diseases such as osteoporosis.
Subject(s)
Biomarkers, Tumor/analysis , Bone Neoplasms/chemistry , Bone Resorption , Giant Cell Tumor of Bone/chemistry , Adenosine Triphosphatases/metabolism , Animals , Cathepsin K , Cathepsins/metabolism , Cattle , Cell Adhesion , Cell Separation , Enzyme-Linked Immunosorbent Assay , Freezing , Humans , In Vitro Techniques , Phenotype , Reproducibility of ResultsABSTRACT
Central giant cell granuloma (CGCG) is a reactive bone lesion that occurs mainly in the jaws. The giant cell tumour (GCT) is a benign locally aggressive neoplasm located near the articular end of tubular bones. Both lesions are characterised histologically by multinucleated giant cells in a background of ovoid to spindle-shaped mesenchymal cells. There is a basic question whether both lesions are separate entities or variants of the same disease. The study of cell cycle-associated proteins may give insights into clarifying such question. The expression of these proteins is also important to determine the cell cycle regulation in both tumours. The purpose of this study was to evaluate the immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in CGCG and GCT. The results demonstrated that, despite the lack of p53 immunoreactivity, all the samples showed wide expression of MDM2. The percentage of Ki-67- and PCNA-positive cells in CGCG was statistically higher than that of GCT Our findings show that CGCG has a higher proliferative activity compared with that of the GCT. Our results also suggest that p53 inactivation by MDM2 expression may be involved in the pathogenesis of giant cell lesions of the jaws and long bones.
Subject(s)
Femoral Neoplasms/pathology , Giant Cell Tumor of Bone/pathology , Granuloma, Giant Cell/pathology , Jaw Neoplasms/pathology , Neoplasm Proteins/analysis , Nuclear Proteins , Adolescent , Adult , Aged , Cell Cycle Proteins/analysis , Cell Division , Child , Child, Preschool , Female , Femoral Neoplasms/chemistry , Giant Cell Tumor of Bone/chemistry , Humans , Immunohistochemistry , Jaw Neoplasms/chemistry , Ki-67 Antigen/analysis , Male , Neoplasm Recurrence, Local , Proliferating Cell Nuclear Antigen/analysis , Proto-Oncogene Proteins/analysis , Proto-Oncogene Proteins c-mdm2 , Staining and Labeling , Statistics, Nonparametric , Tibia/pathology , Tumor Suppressor Protein p53/analysisABSTRACT
A giant cell tumor (GCT) was detected on the distal end of the femur in a 98-wk-old male Fischer 344 rat. The yellowish white mass had expanded, compressing adjacent muscle tissues. The tumor had an osteolytic and relatively homogeneous appearance and was composed of multinuclear giant cells scattered in a mass of mononuclear stromal cells. No osteoid tissue formation was observed. The tumor cells were strongly immunoreactive for ED-1 and some were also positive for alpha-smooth muscle actin, suggesting that the tumor originated from the monocyte/macrophage lineage showing myofibroblastic differentiation. This is the first report concerning spontaneous GCT of bone in a rat.